◆ 会议时间：2027年3月4-6日
◆ 会议地点：瑞士 卢加诺

◆ 会议简介：

2027年ESMO肉瘤和罕见癌症大会将于2027年3月4-6日在瑞士卢加诺举行，会议由欧洲肿瘤内科学会(ESMO)主办。会议将深入探讨罕见实体瘤的诊断、治疗方式、生物学和分子分型方面的最新进展，为与会者提供该专业领域快速发展的全面概述。无论您是经验丰富的肿瘤学家、专业的研究人员、医疗保健专业人士、制药行业领导者还是患者权益倡导者，本次活动都可以为致力于推进肉瘤和罕见癌症患者的护理和改善治疗结果的每个人提供一些帮助。

欧洲肿瘤内科学会（ESMO）成立于1975年，是全球领先的肿瘤内科学专业组织。ESMO是肿瘤学教育和信息的参考学会，现在全球160多个国家和地区拥有超过25,000余名会员；ESMO致力于通过宣促进多学科的癌症护理，支持肿瘤学家的专业发展以及在全球倡导可持续的癌症护理，尽而为癌症患者提供最佳的护理。未经许可禁止复制摘录转载本站任何内容-国际医学会议网（lingyuint.com）。

ESMO Sarcoma & Rare Cancers Congress 2027

Date:
4–6 March 2027

Venue:
Lugano, Switzerland

Scientific Co-Chairs

• Robert Maki - New York, United States
• David Thomas - Sydney, Australia
• Eva Tiensuu Janson - Uppsala, Sweden

摘要征文投稿：

Abstract submission deadlines

点此提交摘要>>>Submit Abstract>>>

• 提交指南>>>ESMO Sarcoma and Rare Cancers 2024 Abstract Regulations

Outcome notifications

Outcome notifications are expected to be made available to first authors and submitters by mid-December 2027.

Abstract presenter registration

The presenting author or the designated replacement presenter must be registered by 10 February 2027. Should the Presenter (or designated replacement presenter) not be registered by the given deadline, the abstract will be excluded from presentation in the ESMO Sarcoma and Rare Cancers Congress 2027 programme and removed from the online programme and publication in the ESMO Sarcoma and Rare Cancers Congress 2027 Abstract Book.

Submission categories

• Central Nervous System (CNS)
• Digestive cancers
• Genitourinary cancers
• Gynaecological cancers
• Head and neck cancers
• Neuroendocrine and Endocrine cancers
• Public Policy, Patient Advocacy and Research methodology
• Sarcoma
• Skin cancers and Melanomas
• Thoracic cancers
• Miscellaneous

Trial in Progress abstracts

Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to the ESMO Sarcoma and Rare Cancers Congress 2027.
It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis.

Presentation of accepted abstracts

The ESMO Sarcoma and Rare Cancers 2027 Scientific Committee will select abstracts for presentation during the Congress based on the following possibilities:

• Proffered Paper – Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.
• Rapid Oral – Short oral presentations by authors presenting data of good quality, followed by expert discussion and perspectives.
• Poster – Paper poster presentation for review and discussion onsite. Presenting authors must attend Congress in person to represent their work. Preparation of an e-Poster file is also mandatory for inclusion in the e-Poster Gallery.
• e-Poster - Electronic poster in PDF format for inclusion in the e-Poster Gallery. Presenting authors of e-Posters are not required to attend the Congress in person to represent their work. Paper posters are not to be prepared, and poster boards will not be provided.

All accepted abstracts will be published online in the ESMO Sarcoma and Rare Cancers Congress 2027 Abstract Book, a supplement to ESMO Rare Cancers Journal.

Publication schedule of accepted abstracts

Abstracts accepted for presentation during the ESMO Sarcoma and Rare Cancers Congress 2027 will be released online according to a schedule which will be available on the ESMO website in due course.

ESMO Merit Awards

A limited number of ESMO Merit Travel Grants to the ESMO Sarcoma and Rare Cancers Congress 2027 are available, upon application, to first authors (= presenters) who submit abstracts considered to be deserving of recognition.
Candidates must be ESMO Members under the age of 40. Selection will be made by the ESMO Sarcoma and Rare Cancers 2027 Scientific Committee on a competitive basis from among the accepted abstracts.